Melodiol Global Health Ltd (PK) (COPHF) Quote

COPHF: effective Jan. 25,2024 a one for 20 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

Volume picking up.
Lots of selling.
Maybe shares changing hands before a pump.
This play could get very intereting.

Canopy people involved here.
Some volume and activity today.
Why?
One day event or a start of a run?
Watching closely and might buy some if the interest is sustained.

$COPHF: Nice investor deck........ worth getting some

Now at 0.068



https://www.otcmarkets.com/otcapi/company/dns/news/document/58326/content



GO $COPHF

no volume,,,1,000shares traded

chart looking tired here

happy holidays ,,

COPHF,,still dropping,,to much bid/ask spread

company needs to make news,,stimulate interest

good morning all,,sorta quiet with COPHF today

Pharma co without any pharma imo. Perfect.

I received an email from Market Index about the news from 12th July. It also was on my broker website (Commsec) but it seems like it disappeared.
Maybe it was released to early or some information was incorrect.
We have to wait for the next news to see what the progress is.

interesting chart,,waiting to see it turn up

Nice! Closing green!

COPHF

$COPHF MMs only showing 5000 shares all the way to 0.161...7 MMs.

Thin to .15s!

COPHF

Nice $COPHF News (ASX:CPH)!

I don't see that news even on its Australian site...
https://www.marketindex.com.au/asx/cph

Thanks for sharing that link...here is the equivalent on the OTC Markets, $COPHF.

https://www.otcmarkets.com/stock/COPHF/news

Here is a link to an Australian website with useful information about $COPHF (ASX:CPH)

https://www.marketindex.com.au/asx/cph

Creso Pharma $COPHF News 12 July 2021

Creso Pharma and Halucenex Life Sciences Inc. welcome Royal Commission into
veteran suicides and clinical studies into psychedelic treatments for addiction and
depression
Highlights
• Australian Federal Government Royal commission into veteran suicides established
after unanimous Australian government vote – highlights the need for treatment
alternatives
• Veteran and defence personnel suicide rates are nearly twice as high as the general
population upon return from service
• Creso and Halucenex commend the push to lower veteran’s suicide rates, which
currently stands at one every two weeks
• Halucenex’s key focus is on mental health treatment for veterans and suicide
prevention
• Royal commission will further highlight the large addressable mental illness market
and the urgent need for alternative treatments
• Halucenex is working with veterans to establish cures and alternative treatment
methods – this work will be continued post merger through The HighBrid Lab
• Creso Pharma and Halucenex also applaud clinical trials at Melbourne’s St. Vincent’s
Hospital to test psilocybin for terminally ill patients experiencing depression or
anxiety - further affirming the strength of Halucenex’s research-focused strategy
• Australian-first clinical trials also scheduled to begin in August at Sydney’s St.
Vincent’s Hospital to test the efficacy of psilocybin compounds in the treatment of
methamphetamine related addictions
• Re-emergence of COVID-19 has resulted in a sharp increase in mental health patients
throughout Australia with Beyond Blue experiencing a 64.8% surge in calls between
January 2021 and January 2019 (AIHW, 2021)
• Study on addiction treatment highlights broad applicability of psychedelic molecules
• Creso Pharma and Halucenex is strongly placed to assist into suicide prevention in
general and in particular war veterans.

Link:
https://files.marketindex.com.au/files/edms/CPH-Royal-Commission.pdf

$COPHF trading at the high of the day and thin to green!

Time to load up!

COPHF

This is a very exciting acqusition for $COPHF...and they had great News this week!

July 06, 2021

Creso Pharma secures first purchase order from Red Light Holland to sell hemp CBD products in the Netherlands
https://wcsecure.weblink.com.au/pdf/CPH/02392377.pdf

$COPHF acquisition of Canada-based Halucenex Life Sciences (March 2021) opens multi billion dollar psychedelic's market potential (Data Bridge Market Research forecasts psychedelic market to reach USD $6.8 billion by 2027).

This will aid $COPHF's future!

Mr. Bruce Linton, leading cannabis and psychedelics entrepreneur and founder of Canopy Growth (Nasdaq: CGC), expected to join as Non-Executive Chairman of The HighBrid Lab's board of directors.

Thanks for sharing that link to the $COPHF article.

$COPHF Creso Pharma (OTCQB: COPHF) and Red Light Holland Merge to Introduce The HighBrid Lab https://tradealert.microcapbull.com/cophf

.12's thin on the ask, nice green start!

COPHF

Almost 2x the $COPHF 10-day average volume. Let's see if it's volume then price.

$COPHF News July 06, 2021

Creso Pharma Limited (ASX:CPH, FRA:1X8) (“Creso Pharma” or the “Company”) is pleased to advise that it has secured its first purchase order (“PO”) from Red Light Holland’s wholly-owned distribution company SR Wholesale B.V. (“SR Wholesale”) for Creso Pharma’s leading range of Swiss manufactured hemp CBD products. This marks the first purchase order between Red Light Holland and Creso Pharma and an important step ahead of the creation of The HighBrid Lab. Both parties are also aggressively pursuing product development initiatives to explore the potential of combining functional mushrooms and other compounds with Creso Pharma’s existing product suite, should the proposed merger with Red Light Holland be approved by shareholders.

Creso Pharma secures first purchase order from Red Light Holland to sell hemp CBD products in the Netherlands
https://wcsecure.weblink.com.au/pdf/CPH/02392377.pdf

$COPHF News! Creso Pharma secures first purchase order from Red Light Holland to sell hemp CBD products in the Netherlands

https://wcsecure.weblink.com.au/clients/cresopharma/v2/headline.aspx?headlineid=61039645

Great informational $COPHF post!

$COPHF Creso delivers second consecutive quarter of record revenue growth https://finfeed.com/small-caps/juniors/creso-delivers-second-consecutive-quarter-record-revenue-growth/

$COPHF Opportunity to Scale Recreational THC Offering Creso Pharma’s Mernova Medicinal Inc. is a licensed cannabis producer in Canada with Craft Designation from the Ontario Cannabis Store, and operates a facility scalable to 200,000 square feet. As the Canadian cannabis market continues to grow, The HighBrid Lab plans to conduct ongoing market reviews to expand Mernova Medicinal Inc.’s penetration and share.

The HighBrid Lab intends to take advantage of the relationships of its board and management team in the Canadian and US markets to pursue potential accretive acquisitions of US THC operators. Having a CSE-listed vehicle will allow the Combined Company to operate in line with state legislation and target US States where the adult use of cannabis is legal.

Recreational cannabis is legal for adult use in 17 states and Washington DC, and medical marijuana is legal in 36 states in the US, providing a number of near term, large market opportunities. In addition, The
HighBrid Lab plans to introduce Red Light Holland branded products within THC markets to continue building brand equity in advance of any potential future changes in the regulatory landscape for Psilocybin.

Creso Pharma Ltd (ASX:CPH | OTC:COPHF) has just confirmed two consecutive quarters of record revenue growth. CPH posted $1.71M revenue this quarter - up from $1.38M in the previous quarter - that’s 24% growth. https://www.nextbiotech.com.au/cph-releases-material-announcement/

Spread tightening up, green now heading into power hour!

COPHF

.174 ready to fall!

COPHF

Creso Pharma Ltd (ASX:CPH | OTC: $COPHF) has just confirmed two consecutive quarters of record revenue growth. https://www.nextbiotech.com.au/cph-releases-material-announcement/

Another site with the $COPHF News

July 01, 2021

CPH releases material announcement
https://www.nextbiotech.com.au/cph-releases-material-announcement/

Full Press: Creso delivers second consecutive quarter of record revenue growth $COPHF


By Trevor Hoey. Published at Jul 1, 2021, in Small Caps

Creso Pharma Limited (ASX:CPH, FRA: 1X8) through its Swiss operations and wholly-owned Canadian subsidiary, Mernova Medicinal Inc. has achieved record sales growth for the June quarter.

This has added to the company’s growing revenue profile that has benefited from multiple purchase orders from various provinces, highlighting increased demand for Mernova’s products in Canada.

To date, Creso Pharma has generated a total of A$1,715,933 in revenue during the June quarter, which marks a 24% increase on the previous quarter (Q1 CY2021: A$1,385,000) and and a 451% increase on the previous corresponding period (Q2 CY2020: A$311,353).

The consistent quarter on quarter growth is underpinned by the strong demand for Mernova’s craft cannabis products and Creso Pharma’s animal and human health CBD products.

Mernova continues to aggressively pursue further near term sales opportunities prior to quarter end.

This provides confidence in the company's scalable recurring revenue model that will increasingly provide income visibility and predictability for the broader group.

Mernova has generated a total of A$1,040,454 in sales to date from purchases from various provinces including the Nova Scotia Liquor Corporation (NSLC), New Brunswick’s only legal cannabis retailer and the Yukon Liquor Corporation for its Ritual Green and Ritual Sticks pre-roll range.

Get our newsletter with an exclusive article straight to your inbox
Your email address
KEEP ME POSTED
Robust demand for animal and human health products
The strong sales performance was assisted by increasing demand for Creso Pharma’s animal and human health CBD products.

Creso Pharma’s Swiss operations have contributed approximately CHF469,083 (A$675,479) to total quarterly revenue growth so far through the sale of the company’s high-quality CBD products for animals and humans.

Recent revenue growth is in line with the company’s strategy of increasing sales in existing key markets, ongoing international expansion and through the introduction of new products.

Creso Pharma has a positive outlook on sales growth, with the expectation that the Red Light Holland (RLH) merger could potentially provide multiple new near term market entries and scale-up opportunities

Enhanced regulatory conditions provide new opportunities
There has also been positive news on the regulatory front with Connecticut becoming the nineteenth state across the US to allow recreational cannabis use.

The state passed legislation on Tuesday, 22 June 2021, which allows people aged 21 and over to possess and consume marijuana beginning 1 July 2021.

The legislative shift is expected to lay the groundwork for a new cannabis industry in the state.


Government representatives anticipate that retail sales of recreational cannabis in the state will commence during 2022.

There has been movement in California as well as Senate Bill 519 (SB519) has now passed through the Californian State Assembly Committee on Public Safety, which is another pivotal step towards the legislation being enacted into law.


SB519 proposes that a wide range of psychedelic substances, including psilocybin, should be legal to use and possess for adults over the age of 21, as well as expunge prior criminal offences for use and possession.

The bill was introduced to progress a more health-focused approach to the use of psychedelic compounds and to address the current mental health crisis in the US. It also marks the ongoing push towards acceptance of psychedelic compounds as an alternative treatment route.

This provides another major market opportunity for Creso Pharma and Red Light Holland ahead of the potential merger to create The HighBrid Lab.

Both parties are currently exploring go to market strategies and opportunities to scale up Mernova’s offering to progress an entry into US markets.

It also favours acquisition target Halucenex.

The HighBrid Lab prepares to tackle US$41 billion US market
The US is anticipated to become the world’s largest cannabis market and reach a value of US$41 billion by 2025.

Creso Pharma is very well positioned through its operations and pending corporate developments to capitalise on this emerging market and unlock considerable value for shareholders.

Commenting on the outstanding sales growth and factors that are likely to provide sustained momentum, particularly in light of the proposed merger, non-executive chairman Adam Blumenthal said, “Recent sales growth across the group is very pleasing and provides a very strong foundation for the remainder of 2021 and beyond.

"We look forward to providing further updates on revenue growth from our existing operations through new product launches and ongoing international expansion efforts."

https://finfeed.com/small-caps/juniors/creso-delivers-second-consecutive-quarter-record-revenue-growth/

Latest news $COPHF - Increased revenue growth

Creso Pharma achieves second consecutive quarter of record
revenue growth

Creso Group revenue growth:

• Total revenue generated during the quarter ended 30 June 2021 (Q2 CY2021) of
A$1,715,933 – a 24% increase on the previous quarter (Q1 CY2021: A$1,385,000)
• Q2 CY2021 revenue marks a 451% increase on the previous corresponding period (Q2
CY2020: A$311,353)
• Strong sales growth witnessed through Swiss operations and wholly-owned Canadian
subsidiary Mernova Medical Inc.
• Multiple purchase orders (“PO”) from various provinces highlight increased demand for
Mernova’s products in Canada and scalable recurring revenue model
• Creso has a positive outlook on sales growth, with potential Red Light Holland (“RLH”)
merger providing multiple new near term market entries and scale up opportunities
• Sales growth represents the second quarter of consecutive record revenue for the Creso
Pharma Group
• Ongoing growth demonstrates Company’s strategy to create consistent revenue
generation across all business divisions

https://clients3.weblink.com.au/pdf/CPH/02390527.pdf

Not a problem. I'm over here in Australia and following this stock for awhile now. It has made some progress over the past few month. Good to see.

Today, Wednesday 30th June is the last day of the financial year in Australia. Should be interesting to see how Creso Pharma is progressing. I certainly which them all the best which is also good for my investment.

Thanks for sharing that information about $COPHF!

News published on Creso Pharma website today:

Creso Pharma Limited (ASX: CPH) (the ‘Company’) requests the voluntary suspension of all quoted securities of the Company, pending an announcement regarding a material sales and revenue update, as announced to ASX on 25 June 2021.

The Company requests that its securities remain in suspension until the release of the aforementioned announcement, which is expected to be lodged on or before Thursday, 1 July 2021.

https://www.cresopharma.com/investor-information

The Highbrid Lab Investor presentation:
https://wcsecure.weblink.com.au/pdf/CPH/02385772.pdf

The stock is currently in a Trading Hold. Awaiting new news.

2 Billion Dollar Company Creators Bruce Linton from Canopy Growth $CGC is an Advisor and Dr. Halperin from MindMed $MMED Created $COPHF!
https://ganjly.com/best-cannabis-stock/

Good morning JJ and $COPHF.

Nice Tweet yesterday...

Creso Pharma, trading on the OTCQB ( $COPHF ) and Red Light Holland merge to form The HighBrid Lab™, a leading global biotech company specializing in recreational products, applied science, technology and innovation. https://t.co/jzcwpN6DD8

$COPHF Video: Creso Pharma Nova Scotia Facility Tour http://www.vimeo.com/343305988

Good morning $COPHF

Creso Pharma Ltd (QB (COPHF) 0.153 +0.011 (7.75%)
Volume: 195,589